ArticleEinstein (Sao Paulo, Brazil)2026
Müllerian-type clear cell adenocarcinoma of the urethra: a case report.
Article in Einstein (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary urethral carcinoma is a rare malignancy, particularly in women, that often presents at an advanced stage with nonspecific symptoms. Among the histological subtypes, clear cell adenocarcinoma is exceptionally uncommon, with approximately only 250 cases reported in the English literature, posing diagnostic and management challenges. We report a case of Müllerian-type clear cell adenocarcinoma of the urethra in a 58-year-old woman. Imaging studies excluded gynecological origins, suggesting derivation from a Müllerian duct remnant or metaplasia. Histologically, the tumor displayed the classic features of clear cell carcinoma, which were supported by positive PAX8 and napsin A immunostaining. Primary urethral adenocarcinoma appears to have poor prognosis in women. Current management relies on a multimodal approach that combines surgery, chemotherapy, and radiotherapy and has shown promising outcomes in recent studies. This case highlights the importance of considering clear cell adenocarcinomas in the differential diagnosis of urethral tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.